Perhaps they do a very early (cheap) deal but I wouldn't imagine anything over say $50m.
Perhaps you may be right about possibly a Summit deal sooner rather than later (if data good) but I am not convinced and still sticking to my thesis (CATB easily fits) . If it turns out their next generation stuff doesn't do much better (i.e. they don't try to for Exon 51, 45, 53) at getting to muscle/skeletal cells (cardiac pretty important in DMD) or If they do another big equity offer (in addition to selling PRV) in the next year or so I'd change my thinking.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
. If it turns out their next generation stuff doesn't do much better (i.e. they don't try to for Exon 51, 45, 53) at getting to muscle/skeletal cells (cardiac pretty important in DMD) or If they do another big equity offer (in addition to selling PRV) in the next year or so I'd change my thinking. 
